John Allan is an Oncology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Sponsor: Weill Medical College of Cornell University
- Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Sponsor: Weill Medical College of Cornell University
- Early Intervention With Acalabrutinib in Patients With High Risk CLL
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- RegeneronProgram year202516 paymentsResearch$575,934openpaymentsdata.cms.gov ↗
- BeOne MedicinesProgram year202517 paymentsResearch$191,077openpaymentsdata.cms.gov ↗
- GenentechProgram year20251 paymentResearch$120,618openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
60.9%Kinase inhibitor47.1%Brukinsa100%Part D≥12 patientsBCL-2 Inhibitor13.8%Venclexta100%Part D<11 patientsAnti-infectives
17.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.4%Valacyclovir100%Part D<11 patientsMetabolism & gastrointestinal
11.6%Corticosteroid11.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”